{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/irritable-bowel-syndrome/prescribing-information/antispasmodic-drugs/","result":{"pageContext":{"chapter":{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs","depth":2,"htmlHeader":"<!-- begin field 73db8e3c-c3b3-4e04-83ca-669f89524ae3 --><h2>Antispasmodic drugs</h2><!-- end field 73db8e3c-c3b3-4e04-83ca-669f89524ae3 -->","summary":"","htmlStringContent":"<!-- begin item 7b9949d2-f8ee-43e2-9681-8a48f460f9b8 --><!-- begin field 3aa77b32-e913-4ca9-bf70-a80000fdf3d4 --><p><strong>Antispasmodic drugs may be used as required for abdominal pain or spasm in irritable bowel syndrome (IBS). Drug options include:</strong></p><ul><li>Direct-acting smooth muscle relaxants such as mebeverine hydrochloride (immediate-release or modified-release), alverine citrate, and peppermint oil.<ul><li>These drugs are less likely to cause adverse effects compared with antimuscarinics such as hyoscine butylbromide and dicloverine.</li><li>Alverine citrate — a dose of 60–120 mg one to three times a day may be used.</li><li>Mebeverine hydrochloride<ul><li>135–150 mg three times a day, dose preferably taken 20 minutes before meals for immediate-release preparation.</li><li>200 mg twice daily for modified-release preparation. </li></ul></li><li>Peppermint oil — one to two capsules taken three times a day for up to 2–3 months if needed, dose to be taken before meals, swallowed whole with water.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field 3aa77b32-e913-4ca9-bf70-a80000fdf3d4 --><!-- end item 7b9949d2-f8ee-43e2-9681-8a48f460f9b8 -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","lastRevised":"Last revised in October 2020","chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","fullItemName":"Management","slug":"management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4d5fd8ca-7934-59cd-9d8e-08ff938b988a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 842a51b7-637f-495a-a197-a75d00726453 --><h3>Contraindications and cautions</h3><!-- end field 842a51b7-637f-495a-a197-a75d00726453 -->","summary":"","htmlStringContent":"<!-- begin item 1f88845f-4f5e-4b95-bef9-a75d00726493 --><!-- begin field 0ac3e170-ebd5-4a4a-af51-a75d00726453 --><p><strong>Do not prescribe direct-acting smooth muscle relaxants (such as mebeverine hydrochloride or alverine citrate) to people with:</strong></p><ul><li>Intestinal obstruction.</li><li>Paralytic ileus.</li></ul><p><strong>Prescribe peppermint oil with caution to people with:</strong></p><ul><li>Sensitivity to menthol.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field 0ac3e170-ebd5-4a4a-af51-a75d00726453 --><!-- end item 1f88845f-4f5e-4b95-bef9-a75d00726493 -->","subChapters":[]},{"id":"e1d007b1-f7ac-56ff-b301-c06c853e9bde","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 88face73-7591-4169-aa73-a75d007278e1 --><h3>Adverse effects</h3><!-- end field 88face73-7591-4169-aa73-a75d007278e1 -->","summary":"","htmlStringContent":"<!-- begin item 7bf05a27-42a1-4de8-8a49-a75d00727968 --><!-- begin field 7fcb5110-642d-4a9d-9fcb-a75d007278e1 --><ul><li><strong>Possible adverse effects of:</strong><ul><li>Alverine citrate include dizziness, dyspnoea, headache, hepatitis, jaundice (resolves with stopping drug), nausea, itch, wheezing.</li><li>Mebeverine hydrochloride include allergic reactions, angio-oedema, rash, urticaria.</li><li>Peppermint oil include allergic reactions, ataxia, bradycardia, headache, muscle tremor, rash.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field 7fcb5110-642d-4a9d-9fcb-a75d007278e1 --><!-- end item 7bf05a27-42a1-4de8-8a49-a75d00727968 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}